Alzamend Neuro 10-K Flags Going Concern, Nasdaq Delisting Risk, and Material Weakness
ALZN sits 61% above its 52-week low of $0.84.
Summary
Alzamend Neuro's 10-K discloses a going concern warning, Nasdaq delisting risk, and a material weakness in internal controls. With only $711K in cash and an $8.8M annual loss, the company urgently needs capital.
Key Events · Earnings and Guidance · ALZN
-
Going Concern Warning
Auditor Haskell & White issued a going concern opinion, citing recurring losses, negative cash flows, and insufficient capital to fund operations for the next twelve months.
-
Nasdaq Delisting Notice
Stockholders' equity of $0.7M as of April 30, 2026 falls below Nasdaq's $2.5M minimum. The company has until September 16, 2026 to submit a compliance plan.
-
Material Weakness in Internal Controls
Management identified a material weakness due to insufficient accounting resources, limiting the ability to perform adequate reviews of journal entries and account reconciliations.
-
Severe Cash Burn
Cash of $711K as of April 30, 2026, with an $8.8M net loss for the fiscal year. The company raised $4.8M in financing during the year but continues to burn cash rapidly.
Analysis · ALZN · Life Sciences
The annual report reveals that the auditor has expressed substantial doubt about Alzamend's ability to continue as a going concern. With cash dwindling to $711K against an $8.8M annual loss, stockholders' equity has slipped below Nasdaq's $2.5M minimum, triggering a delisting notice and a September 16, 2026 deadline to regain compliance. A material weakness in internal controls over financial reporting is also disclosed. For a clinical-stage biotech with no revenue and two early-stage drug candidates, these are existential threats.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 42% of the 419 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALZN was trading at $1.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $0.84 to $3.27. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.